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Sex differences in physiological progression
of idiopathic pulmonary fibrosis
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ABSTRACT: In idiopathic pulmonary fibrosis, incidence is higher in males, and females may have
better survival. The aim of the present study was to determine whether the rate of increase in
desaturation during serial 6-min walk testing would be greater, and survival worse, for males
versus females.
Serial changes in the percentage of maximum desaturation area (DA) over 1 yr were estimated
using mixed models in 215 patients. DA was defined as the total area above the curve created
using desaturation percentage values observed during each minute of the 6-min walk test.
Multivariate Cox regression assessed survival differences.
Adjusting for baseline DA, 6-min walk distance, change in 6-min walk distance over time and
smoking history, the percentage of maximum DA increased by an average of 2.83 and 1.37% per
month for males and females, respectively. Females demonstrated better survival overall, which
was more pronounced in patients who did not desaturate below 88% on ambulation at baseline
and after additionally adjusting for 6-month relative changes in DA and forced vital capacity.
These data suggest that differences in disease progression contribute to, but do not completely
explain, better survival of females with idiopathic pulmonary fibrosis.
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diopathic pulmonary fibrosis (IPF) is a
diffuse parenchymal lung disease of
unknown origin, characterised by alveolar
inflammation, fibrosis of the interstitial space and
pulmonary vascular disruption. Sex discrepan-
cies in this disorder have been suggested for
some time. The incidence and prevalence of
disease have been reported in multiple studies
to be higher in males than in females, with ratios
ranging from ,1.6:1 to 2:1 [1–3]. Prior reports
have also suggested that the female sex is
associated with better survival [4, 5]. The current
hypothesis was that the rate of physiological
progression of disease, as measured by serial
progression in exertional oxygen desaturation,
would be greater in males than females. It has
previously been demonstrated that oxygen
desaturation and serial increases in desaturation
during 6-min walk tests (6MWTs) in IPF patients
correlate with increased mortality [6]; therefore,
the present authors also wanted to assess whether
sex differences in survival remained after adjusting
for longitudinal change in desaturation.
MATERIALS AND METHODS
Study subjects
The present study utilised patients in the data-
base of the University of Michigan Specialized
Center of Research (Ann Arbor, MI, USA) in the
Pathobiology of Fibrotic Lung Disease. Patients
in this database were referred for enrolment in
study protocols for suspected IPF based on typical
symptoms, and physiological and radiographical
findings. Patients with a high-resolution com-
puted tomography (HRCT) scan showing a
definite pattern of usual interstitial pneumonia
(UIP) were not required to undergo a surgical
lung biopsy [7–10]. Patients were treated with
varied treatment regimens, which included the
following: no therapy; prednisone alone; predni-
sone with an additional immunosuppressive
agent, including azathioprine, cyclophosphamide,
methotrexate or mycophenolate mofetil; investi-
gational agents, including bosentan, interferon-c,
GC1008 anti-transforming growth factor-b
antibody, pirfenidone, tetrathiomolybdate or
zileuton; or miscellaneous agents, including N-
acetylcysteine or colchicine (table 1). Therapy
decisions were made by the treating clinician.
The lack of a prospectively defined treatment
regimen, varying lengths of therapy and the
overlap of treatment regimens precluded the
ability to evaluate the effect of treatment on serial
change in pulmonary function, 6MWT or survival;
there is little evidence to date that any of these
treatments were effective in improving outcomes.
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In total, 10 of the patients (nine males and one female)
eventually underwent lung transplantation. Patients with
underlying connective tissue disease, obvious occupational
exposure or a histopathologic pattern other than UIP were
excluded. Approval for the use of these data was obtained
from the Institutional Review Board of the University of
Michigan (Ann Arbor). A subgroup of these patients has been
previously described [6, 7, 10–14].
Study design
The study consisted of a mixed models analysis to determine
whether exertional hypoxaemia in IPF deteriorates more
rapidly in males than females, adjusting for baseline desatura-
tion area (DA), baseline 6MWT distance (6MWD), change in
6MWD over time and smoking history. Several survival
models were also constructed, initially adjusting for age,
smoking history, baseline DA and diffusing capacity of the
lung for carbon monoxide (DL,CO) % predicted. In a subset of
physiologically milder patients who did not desaturate below
88% pred during the baseline 6MWT, a 6-month relative
change in both DA and forced vital capacity (FVC) % pred was
also included.
Methods
DA was defined as the total area above the curve created using
desaturation percentage values observed during each minute
of the 6MWT, thereby summing up the differences between an
arterial oxygen saturation (Sa,O2) of 100% and the patient’s
Sa,O2 at each minute (fig. 1) [6]. For example, a patient with an
Sa,O2 of 98% at each minute during the 6MWT would have a
DA of 12 ((100-98)66512). For safety, the 6MWT was stopped
when patients reached an Sa,O2 of 86%, and a desaturation
score of 14% was assigned for that minute and all subsequent
minutes of the 6MWT; thus, the maximum possible DA score
(DAmax) for an individual is 1466584. A higher DA indicates
higher overall quantity of desaturation during the 6MWT.
Statistical analysis
Baseline characteristics were compared using an unpaired two-
sample t-test. The mixed models analysis was performed using
PROC MIXED (SAS 9.1.2; SAS Institute Inc., Cary, NC, USA),
which adjusts appropriately for missing data due to attrition.
In this mixed model, all DA values were divided by 84
(DAmax) and multiplied by 100, so that parameters estimate
change in the % DAmax. In order to assess survival differences
between males and females, multivariate Cox regression
models were used. Follow-up time was based on date of
diagnosis, either by open lung biopsy or diagnostic HRCT. An
initial survival analysis, adjusting for sex, age, baseline DA,
DL,CO % pred and smoking status, was performed in 179
patients with available data. Additional analyses were then
performed on the 103 patients who did not desaturate below
88% on the baseline 6MWT. Following this, a subset of those
patients in whom serial 6MWT data were available (n572) was
TABLE 1 Treatments administered to 215 patients#
Males Females p-value
Subjects n 142 73
No treatment 23 (16.2) 12 (16.4) 0.96
Prednisone alone 10 (7.0) 8 (11.0) 0.33
Prednisone + cytotoxic agent" 64 (45.1) 26 (35.6) 0.18
Cytotoxic agent alone" 5 (3.5) 1 (1.4) 0.36
Investigational agent+ 43 (30.3) 23 (31.5) 0.85
Miscellaneous1 31 (21.8) 15 (20.5) 0.75
Data are presented as n (%), unless otherwise stated. #: some patients received
more than one treatment regimen, so total is .100%; ": azathioprine,
cyclophosphamide, methotrexate or mycophenolate mofetil; +: bosentan,
interferon-c, GC1008 anti-transforming growth factor-b antibody, pirfenidone,
tetrathiomolybdate, or zileuton; 1: N-acetylcysteine or colchicine.
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FIGURE 1. Schematic showing calculation of desaturation area. Sa,O2: arterial
oxygen saturation. &: desaturation area. Reproduced and modified from [6] with
permission from the publisher.
TABLE 2 Baseline characteristics for 215 patients with
idiopathic pulmonary fibrosis
Males Females p-value
Subjects n 142 73
Age yrs 63.0 64.2 0.39
Baseline DA (% DAmax) 59.0 (70.2) 60.1 (71.5) 0.81
Baseline desaturation ,88%# 37.3 35.6 0.68
FVC % pred 64.7 65.8 0.68
DL,CO % pred 44.0 44.9 0.73
Arterial blood pH 7.42 7.43 0.64
Pa,CO2 mmHg 38.8 38.6 0.79
Pa,O2 mmHg 75.1 73.5 0.17
Resting Sa,O2 % 94.3 94.5 0.81
6MWD m 275.1 240.1 0.18
Former or current smoker % 82.4 63.0 0.002
Data are means, unless otherwise stated. DA: desaturation area; % DAmax:
percentage of maximum possible DA score of 84; FVC: forced vital capacity;
% pred: % predicted; DL,CO: diffusing capacity of the lung for carbon monoxide;
Pa,CO2: arterial carbon dioxide tension; Pa,O2: arterial oxygen tension; Sa,O2:
arterial oxygen saturation; 6MWD: 6-min walk distance. #: percentage of
patients. 1 mmHg50.133 kPa.
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examined. For each of these patients, a 6-month predicted DA
value was obtained from individual regression lines, provided
that each patient was able to perform at least two 6MWTs
within the first 12 months of follow-up and was still alive at
the 6-month time mark. Relative change in DA was calculated
by subtracting the baseline value from the 6-month predicted
value and dividing by the baseline value, with follow-up
commencing at the moment a patient trajectory became
available for analysis. This method was also used to calculate
6-month relative change in FVC % pred. Sex-specific survival
curves were constructed, adjusting for the average values of 6-
month relative change in DA, baseline DA, age, smoking
history, DL,CO % pred, FVC % pred and 6-month relative
change in FVC % pred. In all of the survival analyses, two
mortality end-points were considered: 1) death following
diagnosis, regardless of transplant status; and 2) death
following diagnosis, with censoring at time of transplant.
RESULTS
Baseline characteristics
Baseline demographic data for all 215 patients are presented in
table 2. There was no significant difference in most baseline
variables except the percentage of males versus females who
were former or current smokers. Due to this, the rest of the
analyses were adjusted for smoking history.
Repeated measures analysis
Males were associated with a more rapid increase in DA over
time compared with females, with the % DAmax increasing by
2.83% per month for males versus 1.37% per month for females.
Thus, after 1 yr, the sex difference in % DAmax was 17.5%
(p50.01). This indicates that the progression of exertional
hypoxaemia was more rapid in males (table 3).
Survival analysis
A multivariate Cox regression model evaluating sex differ-
ences, adjusted for age, smoking history, DL,CO % pred and
DA, demonstrated a statistically significant survival advantage
for females (hazard ratio (HR) 0.63 (95% confidence interval
(CI) 0.41–0.97); p50.04; table 4). When FVC % pred was
included in the multivariate model, it was found to be a
nonsignificant predictor of survival, and the corresponding sex
HR continued to favour females (p50.048). Censoring these
patients at the time of transplant did not substantially change
the results (0.61 (0.39–0.94); p50.03).
Additionally, the impact of sex on patients with less severe
disease was examined, since it is in these patients that there
would be the most opportunity for exertional hypoxaemia to
change over time and subsequently influence survival.
Therefore, a survival analysis was performed on 103 patients
TABLE 3 Mixed models analysis for predictors of change in percentage of maximum possible desaturation area (% DAmax) over
time#
Predictor variable Change in % DAmax p-value
Time if male months 2.83 ,0.0001
Time if female months 1.37 0.01
Female -1.25 0.14"
Baseline % DAmax 0.86 ,0.0001
6MWD m -0.02 ,0.0001
Interaction between distance walked and time m per month -0.006 ,0.0001+
Former or current smoker versus nonsmoker 0.49 0.59
6MWD: 6-min walk distance. #: 215 patients; ": no significant difference was seen in desaturation area (DA) between sexes at baseline; it was the rate of change in DA
over time that differed significantly between sexes; +: the significance of this interaction indicates that a small drop in % DAmax was experienced by patients who increased
their walk distance over time.
TABLE 4 Multivariate survival model examining the impact
of sex#
Variable HR (95% CI) p-value
Female 0.63 (0.41–0.97) 0.04
Age yrs 1.00 (1.00–1.05) 0.04
DL,CO % pred 0.18 (0.04–0.82) 0.03
Desaturation area 1.02 (1.00–1.03) 0.009
Former or current smoker 1.06 (0.68–1.65) 0.80
Analysis adjusted for age, diffusing capacity of the lung for carbon monoxide
(DL,CO) % predicted (% pred), desaturation area and smoking history. HR:
hazard ratio; CI: confidence interval. #: 179 patients.
TABLE 5 Multivariate survival model examining the impact
of sex in patients who did not desaturate below
88% during baseline 6-min walk test#
Variable HR (95% CI) p-value
Female 0.48 (0.26–0.89) 0.02
Age yrs 1.03 (0.99–1.06) 0.11
DL,CO % pred 0.20 (0.03–1.26) 0.09
Desaturation area 1.03 (1.01–1.04) 0.001
Former or current smoker 1.02 (0.57–1.82) 0.95
Analysis adjusted for age, diffusing capacity of the lung for carbon monoxide
(DL,CO) % predicted (% pred), desaturation area and smoking history. HR:
hazard ratio; CI: confidence interval. #: n5103.
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who did not desaturate below 88% during their first 6MWT.
In this analysis, the better survival of females was even more
pronounced than in the overall patient population (0.48 (0.26–
0.89); p50.02; table 5) and remained marginally significant at
the same order of clinical significance, when censoring patients
at time of transplant (0.57 (0.31–1.05); p50.07).
Following this, 6-month relative change in DA, baseline FVC %
pred and 6-month relative change in FVC % pred were added
to the model (n572; table 6), as increase in DA and decrease in
FVC have been previously demonstrated to be predictive of
survival in IPF [6]. In this model, the female sex was still
associated with better survival (0.38 (0.15–0.95); p50.04).
Baseline DA, 6-month relative change in DA and 6-month
relative change in FVC were also significant independent
predictors of survival in this model. Adjusted survival curves
are presented in figure 2 for the average profile patient, similar
except with regard to sex: age562.85 yrs; DL,CO548.3% pred;
baseline DA547.52 (56.57% of DAmax); 6-month relative
change in DA as a percentage of baseline515.1%; probability
of smoking history577%; FVC571% pred; and 6-month
relative change in FVC % pred as a percentage of base-
line55.2%. Notably, only one patient in this group underwent
transplant during the follow-up period, and censoring that
patient at the time of transplant did not substantially change
the results of the analysis.
DISCUSSION
Sex discrepancies in IPF have been suggested by several
investigators. These differences include a higher prevalence of
disease and higher mortality in males. Since it has been
suggested that serial measures of pulmonary physiology,
particularly exertional desaturation, strongly influence survi-
val in IPF, the current authors hypothesised that the rate of
physiological progression of disease would be greater in males
than females. In this study several important observations
were made, including: 1) males with IPF demonstrate more
rapid deterioration in exertional desaturation over time
compared with females; 2) survival is worse in males
compared with females; and 3) better survival for females
persists after additional adjustment for relative change in
exertional desaturation and FVC % pred.
The importance of longitudinal change in FVC, DL,CO and
6MWT has been confirmed by several groups [6, 15, 16], but
sex differences in longitudinal change in physiological para-
meters have not been formerly reported. Thus, the present
study explored and documented a sex difference in the rate of
deterioration in exertional desaturation. While it could be
argued that the difference in physiological trajectories was due
to systematic differences in disease stage, there was no
significant difference in baseline pulmonary function measure-
ments or DA between sexes, and the change in DA over time
was adjusted for age, smoking history, DL,CO % pred and
baseline DA. The aetiology of the sex-specific difference in
disease progression, however, is not readily obvious.
The current study also demonstrates better survival of females
with IPF compared with males, after adjusting for age,
smoking history, DL,CO % pred and DA. This is in contrast to
a lesser-powered retrospective analysis of 99 patients with IPF,
where sex was not detected to be a significant predictor of
survival in a multivariate analysis adjusted for measures of
lung function, age and smoking history [17]. In older literature,
several studies suggest a survival advantage for females [3, 18]
and several do not [19, 20], but this may be due to lack of
power and a mixture of diagnoses prior to the development of
the clinical, radiological and pathological diagnostic methods
now in place. However, most recent reports suggest a survival
advantage for females, with relative risks of death for males
compared with females ranging 1.4–2.3 [4, 5].
Vital statistics in the USA indicate that the unadjusted average
life expectancy for males is 74.7 yrs and for females 80 yrs [21].
In the present study, physiological parameters known to
TABLE 6 Multivariate survival model examining the impact
of sex in patients who did not desaturate below
88% during baseline 6-min walk test (6MWT) and
in whom 6MWT trajectory data were available#
Variable HR (95% CI) p-value
Female 0.38 (0.15–0.95) 0.04
Age yrs 1.02 (1.02–0.99) 0.23
DL,CO % pred 2.93 (0.20–41.9) 0.43
Desaturation area 1.05 (1.02–1.08) 0.0006
6-month relative change in DA 2.91 (1.51–5.60) 0.001
Former or current smoker 0.71 (0.28–1.79) 0.43
FVC % pred 0.35 (0.05–2.53) 0.30
6-month relative change in FVC % pred 1.57 (1.15–2.13) 0.004
Analysis adjusted for age, diffusing capacity of the lung for carbon monoxide
(DL,CO) % predicted (% pred), desaturation area (DA), 6-month relative change
in DA, smoking history, forced vital capacity (FVC) % pred, and 6-month relative
change in FVC. HR: hazard ratio; CI: confidence interval. #: n572.
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FIGURE 2. Comparison of survival between males (–––––) and females
(..........) with idiopathic pulmonary fibrosis who did not desaturate below 88% on
baseline 6-min walk test (n572), adjusted for the following mean values:
age562.85 yrs; diffusing capacity of the lung for carbon monoxide548.3%
predicted; baseline desaturation area (DA)547.52; 6-month relative change in DA
as a percentage of baseline515.1%; probability of smoking history577%; baseline
forced vital capacity (FVC)571% pred; and 6-month relative change in FVC % pred
as a percentage of baseline55.2%.
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influence survival in IPF were controlled for, and significant
differences in survival between males and females were still
seen, well beyond the magnitude of survival differences seen
in the general population. Interestingly, in the current subjects
who did not desaturate below 88% on the baseline 6MWT, the
survival advantage for females was even more pronounced.
The data are also strengthened by the rigorous definition of
UIP using a clinical, radiographical and pathological format.
As DA trajectory and survival both differed between sexes, the
hypothesis was also tested that relative change in DA may
influence survival and help to explain sex differences. For this,
the focus was on those patients with oxygen saturation above
88% during their baseline 6MWT and in whom serial 6MWT
data were available. Specific examination of this group was
chosen because these patients have less severe disease and,
thus, theoretically more room to deteriorate during the
observation period of the study, allowing better evaluation of
how change in physiology affects survival. In the present
survival analysis, FVC % pred and 6-month relative change in
FVC % pred were also included in the model, as change in FVC
has been previously shown to be a significant predictor of
survival [6]. Other predictors included sex, age, smoking
history and DL,CO % pred. The survival advantage for females
became even more pronounced (HR 0.38 (95% CI 0.15–0.95);
p50.04). Consequently, these data suggest that, while differ-
ences in disease progression probably contribute to better
survival for females, the female sex is still associated with
enhanced survival, independent of relative change in DA and
FVC. A smaller series of IPF patients did not suggest that sex
affected the predictive value of longitudinal change in
exertional desaturation on survival [22]. Differences may
reflect reduced power due to sample size or methodology
used to define 6MWT desaturation. Additional prospective
data collection is required to better define these differences.
Importantly, IPF is not the only fibrotic disorder in which
sexual dimorphism has been noted. Females are relatively
protected from fibrotic diseases involving the liver and kidney.
Males with chronic renal disease progress more rapidly than
females to end-stage renal failure [23]. Population data also
suggest end-stage liver disease, in the form of cirrhosis, is
much more common in males than females (ranging from 2.3:1
to 2.6:1) [24]. In both end-stage renal and hepatic disease, a
potential role for oestrogen has been proposed, which appears
to be protective in animal models [25–27]. The average age of
females in the present study was 64.2 yrs, suggesting that the
majority of females would have been post-menopausal, with
low oestrogen levels. Conversely, a prior report of bleomycin-
induced pulmonary fibrosis in rats demonstrated diminished
fibrosis in female ovariectomised rats; the fibrotic response
was restored with oestradiol replacement [28]. Thus, an exact
explanatory mechanism for the present data is not readily
obvious, and the role of oestrogen on the fibrotic process must
be further clarified. Better understanding of sex differences in
disease progression may offer further insight into the
pathogenesis of the disease.
There are limitations to the current study. The data are
retrospective and potentially subject to several types of bias.
Treatments were not systematically assigned. One sex may
tend to present at different stages of the disease compared with
the other, although this was not readily apparent in the present
cohort, based on predictors studied as part of table 2. While
females tend to be more frequent seekers of healthcare in
general, they are also less likely to receive subspecialty
referrals [29]. Furthermore, the survival data may be biased
by a differential presence of comorbidities, such as cardiovas-
cular disease. The development of pulmonary vasculopathy
was not prospectively assessed, which may be important as
desaturation has been suggested to be associated with a greater
prevalence of pulmonary hypertension in IPF patients [30]. A
strength of the present study, however, is that the longitudinal
analysis of DA was adjusted for factors that could potentially
bias the results, including baseline DA, distance walked,
change in distance walked over time, age and smoking status.
Furthermore, patient diagnosis was assigned based on the
current standard of care, a multidisciplinary clinical, radio-
logical and pathological process.
In conclusion, the current study has determined that while
differences in the rate of physiological progression probably
contribute to survival differences between males and females,
there may be other uncharacterised sex-related influences on
survival. Prospective validation of the data is required to
define potential therapeutic implications of these data.
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